Intraperitoneal Chemotherapy Improves Survival in Ovarian Cancer

Share this content:
IP as opposed to IV chemo is associated with better survival in patients with advanced ovarian cancer.
IP as opposed to IV chemo is associated with better survival in patients with advanced ovarian cancer.

Intraperitoneal (IP) as opposed to intravenous (IV) chemotherapy is associated with better survival in patients with advanced ovarian cancer, according to a recent study published online ahead of print in the Journal of Clinical Oncology.

Researchers led by Devansu Tewari, MD, of Kaiser Permanente Irvine Medical Center retrospectively observed data from the Gynecologic Oncology Group which included 876 patients at a median follow-up of 10.7 years.

They found that median survival with IP was 61.8 months compared to 51.4 months with IV.

Additionally, IP was associated with a 23 percent decreased risk of death, and improved survival of those with gross residual disease. Death risk was decreased further by 12 percent for each cycle of IP chemotherapy that was completed.

RELATED: No Change in Ovarian Cancer Survival with Aggressive Surgery

Younger patients were found to be more likely to complete IP regimen, with a 5 percent decreased probability of completion with each year of age.

“The advantage of IP over IV chemotherapy extends beyond 10 years,” the authors concluded. “Survival improved with increasing number of IP cycles.”

Reference

  1. Tewari, Devansu, et al. "Long-Term Survival Advantage and Prognostic Factors Associated With Intraperitoneal Chemotherapy Treatment in Advanced Ovarian Cancer: A Gynecologic Oncology Group Study." Journal of Clinical Oncology. doi: 10.1200/JCO.2014.55.9898. [epub ahead of print]. March 23, 2015.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs